| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_4f6be7b5f316f050e9151b3afd8936f7 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-76
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-56
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2510-02 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2887
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2896
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-3061
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K51-1069
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-00 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-63
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-13 |
| filingDate |
2005-12-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_859352c889f82fbd2609317bfdfe0b6f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f986f58b5592617f672070931a584eb3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c481b7bfb96f9e2172bfd49213cc777b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_69c3bc4a43030ae1232de13fe8a3ed22 |
| publicationDate |
2014-01-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
KR-20140003660-A |
| titleOfInvention |
Cytotoxic antibodies against type V lymphoid hematopoietic proliferation |
| abstract |
The invention relates to a monoclonal antibody to a CD20 antigen, wherein the variable region of each light chain is encoded by a sequence that shares at least 70% identity with murine nucleic acid SEQ ID NO: 5, wherein the variable region of each heavy chain is a murine nucleic acid sequence number : 7, and wherein the constant region of these light and heavy chains is a constant region derived from non-murine species; The invention also relates to the use of such antibodies in the manufacture of medicaments for the activation of Fc [gamma] RIIIA receptors and for the treatment of drugs, in particular leukemias or lymphomas, in immuno-effect cells. |
| priorityDate |
2004-12-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |